drugset / Trial / NCT00782418

A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

NCT00782418

Phase 1 Completed 27 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindDiagnostic

Summary

This study will compare graded glucose infusion (GGI) to the hyperglycemic clamp (HGC) for assessment of glucose-dependent insulin secretion (GDIS) using exenatide as a probe.

Timeline

Start
2008-09
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide 1.5 ug Subcutaneous
Comparator Exenatide Peptide 5 ug Subcutaneous